Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow [17]

Leukemia

Volumn 21, Issue 7, 2007, Pages 1559-1602

  Gattenlohner, S ^a   Peter, C ^a   Bonengel, M ^a   Einsele, H ^a   Bargou, R ^a   Muller Hermelink H K ^a   Marx, A ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; DNA; JANUS KINASE 2; PHENYLALANINE; RNA; VALINE;

BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LETTER; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; WILD TYPE; BLOOD; BONE MARROW; COMPARATIVE STUDY; GENETICS; MISSENSE MUTATION;

BLOOD; BONE MARROW; DNA; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; RNA;

EID: 34250877384     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404701     Document Type: Letter

References (8)

1. Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M et al. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagn 2006; 8: 299-304.
2. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173-2181.
3. Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007; 109 1334-1335.
4. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006; 1: 240-245.
5. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
6. Gattenlohner S, Bonengel M, Muller-Hermelink HK. Optimized RT-PCR based detection of specific genetic abnormalities within malignant hematopoietic disorders. Pathologe 2006; 27: 182-187.
7. Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E et al. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol 2006; 1: 1-2. E-pub ahead of print.
8. Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn 2007; 9: 42-46.